19
Pharmakologie (Fach) / Cornell Heme/Onc (Lektion)
Anzeige
- Zosyn Piperacillin/Tazobactam Use:- Neutropenic fever
- Atrovent Ipratropium
- Prophylaxis during chemotherapy Valacyclovir (Valtrex), Psaconazole
- Venetoclax Bcl-2 inhibitor Use:- CLL with 17p mutation or relapse Adverse effects:- Tumor lysis syndrome- Neutropenia, thrombocytopenia
- Decitabine Hypomethylating agent, Cytidine analog Use:- AML- Myelodysplastic syndromes
- Velcade Bortezomib Proteosome inhibitor Use:- Relapsed multiple myeloma and mantel cell lymphoma
- Daratumumab CD38 inhibitor (overexpressed by multiple myeloma cells)
- Revlimid Lenalidomide Use:- Multiple myeloma- Mantel cell lymphoma- Deletion 5q myelodysplastic syndrome
- Dilaudid Hydromorphine hydrochloride
- Keflex Cefalexin 1st generation cephalosporine
- Anzeige
- Midostaurin Multi-targeted protein kinase inhibitor Use:- AML positive for FLT3- MDS
- Clofarabine Purine nucleotide antimetabolite Use:- ALL- AML- Bridge to hematopoietic stem cell transplant
- Jakafi Ruxolitinib JAK1/2 kinase inhibitor Use:- Myelofibrosis- Polycythemia vera unresponsive to hydroxyurea- Pretreatment of BMT to shrink spleen
- Sevelamer Phosphate binding drug Use:- Hyperphosphatemia in patients with CKD
- Vyxeous Cytarabine and daunorubicin 7+3 Use- t-AML- AML-MRC (myelodysplasia related changes)
- Neoral Cyclosporine
- Actinium-Lintuzumab Targets CD33 Use:- Older patients with previously untreated AML unfit for chemotherapy
- Sorafenib Tyrosine protein kinase inhibitor (VEGF, PDGFR, Raf family kinases) Use:- Renal cell carcinoma- Unresectable HCC- Thyroid cancer- AML (FLT3-ITD+)
- Nilotinib Tyrosine kinase inhibitor Use:- Imatinib-resistant CML